ABSTRACT
Hemorrhagic rashes are observed in a wide variety of conditions, ranging from harmless to life-threatening. This review offers a stepwise approach, which helps limit the possible differential diagnoses based on the clinical manifestations and the clinical picture. The most common and most important conditions, including infectious, coagulation and embolic disorders, vasculitides, and vasculopathies, are briefly reviewed focusing on morphology. Dermatologists often need to distinguish among infectious, reactive, or autoimmune etiologies of the rash and determine if the condition is dangerous or even life-threatening in order to make the right decision. Dermatologic expertise provides vital input in the diagnosis and care of complex interdisciplinary patients, such as those with sepsis, purpura fulminans, and thrombotic thrombocytopenic purpura.
Subject(s)
Exanthema/pathology , Skin/pathology , Diagnosis, Differential , Exanthema/complications , Exanthema/diagnosis , Hemorrhage/etiology , Hemorrhage/pathology , HumansABSTRACT
Alterations in lipid metabolism in cancer cells impact cell structure, signaling, and energy metabolism, making lipid metabolism a potential diagnostic marker and therapeutic target. In this study, we combined PET, desorption electrospray ionization-mass spectrometry (DESI-MS), nonimaging MS, and transcriptomic analyses to interrogate changes in lipid metabolism in a transgenic zebrafish model of oncogenic RAS-driven melanocyte neoplasia progression. Exogenous fatty acid uptake was detected in melanoma tumor nodules by PET using the palmitic acid surrogate tracer 14(R,S)-18F-fluoro-6-thia-heptadecanoic acid ([18F]-FTHA), consistent with upregulation of genes associated with fatty acid uptake found through microarray analysis. DESI-MS imaging revealed that FTHA uptake in tumors was heterogeneous. Transcriptome and lipidome analyses further highlighted dysregulation of glycerophospholipid pathways in melanoma tumor nodules, including increased abundance of phosphatidyl ethanolamine and phosphatidyl choline species, corroborated by DESI-MS, which again revealed heterogeneous phospholipid composition in tumors. Overexpression of the gene encoding lipoprotein lipase (LPL), which was upregulated in zebrafish melanocyte tumor nodules and expressed in the majority of human melanomas, accelerated progression of oncogenic RAS-driven melanocyte neoplasia in zebrafish. Depletion or antagonism of LPL suppressed human melanoma cell growth; this required simultaneous fatty acid synthase (FASN) inhibition when FASN expression was also elevated. Collectively, our findings implicate fatty acid acquisition as a possible therapeutic target in melanoma, and the methods we developed for monitoring fatty acid uptake have potential for diagnosis, patient stratification, and monitoring pharmacologic response. SIGNIFICANCE: These findings demonstrate the translational potential of monitoring fatty acid uptake and identify lipoprotein lipase as a potential therapeutic target in melanoma.
Subject(s)
Fatty Acids/metabolism , Glycerophospholipids/metabolism , Melanocytes/pathology , Melanoma/pathology , Zebrafish/metabolism , Animals , Energy Metabolism , Fatty Acid Synthases/genetics , Fatty Acid Synthases/metabolism , Humans , Lipoprotein Lipase/genetics , Lipoprotein Lipase/metabolism , Melanocytes/metabolism , Melanoma/genetics , Melanoma/metabolism , Metabolomics , Microphthalmia-Associated Transcription Factor/genetics , Transcriptome , Tumor Cells, Cultured , Zebrafish/genetics , Zebrafish Proteins/genetics , ras Proteins/genetics , ras Proteins/metabolismABSTRACT
BACKGROUND: Mutations in tetratricopeptide repeat domain 7A (TTC7A) and its mouse orthologue, Ttc7, result in a multisystemic disease, mostly affecting the epithelial barriers and immune system. Despite successful hematopoietic stem cell transplantation, ongoing progression of gastrointestinal manifestations can be life-threatening in TTC7A-deficient patients. OBJECTIVE: We sought to identify whether TTC7A mutations dysregulate epithelial cells only or whether a cell-intrinsic defect in lymphocytes or other cells contributes to disease manifestations. METHODS: Ttc7-mutated (Ttc7fsn/fsn) mice were crossed to generate double-mutant (Rag2-/-Ttc7fsn/fsn) and triple-mutant (Rag2-/-IL2rg-/-Ttc7fsn/fsn) mice. These models, together with bone marrow chimeras, were used to explore the role of adaptive and innate lymphocytes in the flaky skin phenotype. The effect of the Ttc7fsn/fsn mutation on stromal cells was tested in a xenograft model in conjunction with transcriptomic analysis of Ttc7fsn/fsn fibroblasts. RESULTS: We observed that the severity of epithelial hyperproliferation was accentuated by lymphocytes, whereas the phenotype was not induced by transfer of Ttc7-mutated hematopoietic cells. Furthermore, mice completely lacking the lymphocytic compartment were not protected from epithelial hyperproliferation. Ttc7-mutated mouse fibroblasts expressed increased transcript levels of insulin-like growth factor 1 (Igf1) and the antimicrobial protein regenerating islet-derived protein 3γ (Reg3γ). In a xenograft model Ttc7-mutated fibroblasts markedly increased epithelial proliferation of keratinocytes. Thus Ttc7-mutated fibroblasts were identified as potent instigators of epithelial hyperproliferation. CONCLUSION: Our results reveal a previously unsuspected fundamental cell-extrinsic role of Ttc7. We have identified potential candidates for molecularly targeted treatment strategies that will need to be evaluated in future preclinical studies.
Subject(s)
Cell Proliferation , Dermatitis/immunology , Epithelial Cells/immunology , Fibroblasts/immunology , Genetic Diseases, Inborn/immunology , Lymphocytes/immunology , Mutation , Proteins/immunology , Animals , BALB 3T3 Cells , Dermatitis/genetics , Dermatitis/pathology , Epithelial Cells/pathology , Fibroblasts/pathology , Genetic Diseases, Inborn/genetics , Genetic Diseases, Inborn/pathology , Humans , Lymphocytes/pathology , Mice , Mice, Knockout , Proteins/geneticsABSTRACT
Mitogen-activated protein kinase (MAPK) pathway antagonists induce profound clinical responses in advanced cutaneous melanoma, but complete remissions are frustrated by the development of acquired resistance. Before resistance emerges, adaptive responses establish a mutation-independent drug tolerance. Antagonizing these adaptive responses could improve drug effects, thereby thwarting the emergence of acquired resistance. In this study, we reveal that inflammatory niches consisting of tumor-associated macrophages and fibroblasts contribute to treatment tolerance through a cytokine-signaling network that involves macrophage-derived IL-1ß and fibroblast-derived CXCR2 ligands. Fibroblasts require IL-1ß to produce CXCR2 ligands, and loss of host IL-1R signaling in vivo reduces melanoma growth. In tumors from patients on treatment, signaling from inflammatory niches is amplified in the presence of MAPK inhibitors. Signaling from inflammatory niches counteracts combined BRAF/MEK (MAPK/extracellular signal-regulated kinase kinase) inhibitor treatment, and consequently, inhibiting IL-1R or CXCR2 signaling in vivo enhanced the efficacy of MAPK inhibitors. We conclude that melanoma inflammatory niches adapt to and confer drug tolerance toward BRAF and MEK inhibitors early during treatment.
Subject(s)
Inflammation/enzymology , Inflammation/pathology , MAP Kinase Signaling System , Melanoma/enzymology , Melanoma/pathology , Skin Neoplasms/enzymology , Skin Neoplasms/pathology , Animals , Cell Line, Tumor , Cell Proliferation/drug effects , Chemokine CXCL1/metabolism , Fibroblasts/drug effects , Fibroblasts/metabolism , Humans , Interleukin-1/metabolism , Interleukin-1beta/metabolism , Interleukin-8/metabolism , Ligands , MAP Kinase Signaling System/drug effects , Macrophages/drug effects , Macrophages/metabolism , Mice, Knockout , Mitogen-Activated Protein Kinase Kinases/antagonists & inhibitors , Mitogen-Activated Protein Kinase Kinases/metabolism , NF-kappa B/metabolism , Protein Kinase Inhibitors/pharmacology , Proto-Oncogene Proteins B-raf/metabolism , Proto-Oncogene Proteins c-bcl-2/metabolism , Receptors, Interleukin-1/metabolism , Receptors, Interleukin-8B/metabolism , Stromal Cells/metabolism , Stromal Cells/pathologyABSTRACT
Purpuric lesions appear in acral distribution in a variety of conditions and often provide clues to the clinical diagnosis. Purpuric means "hemorrhagic"-that is, the lesions do not blanch from pressure. This review focuses on dermatoses that produce hemorrhagic lesions in acral distribution from the large groups of the vasculitic diseases and their mimics. Cutaneous small vessel vasculitis is confined to the skin, involves mainly postcapillary venules, and has the hallmark manifestation of palpable purpura. Henoch-Schönlein purpura is an immune complex-mediated systemic vasculitis of the small vessels with manifestations from the skin, joints, kidneys, and gastrointestinal system. Only cases where the immune complexes contain immunoglobulin A type are classified as Henoch-Schönlein purpura. Cryoglobulinemic vasculitis is induced by the deposition of cold-precipitated immune complexes in the small vessels. Urticarial vasculitis comprises a spectrum of conditions with the characteristic course of chronic urticaria, with wheals that persist longer than 24 hours, leave hyperpigmentation, and have leukocytoclastic vasculitis on histologic examination. Polyarteritis nodosa is a rare multisystem, segmental necrotizing vasculitis of mainly the medium-sized vessels. Pigmented purpuric dermatoses are chronic benign dermatoses characterized by petechiae, purpura, and increased skin pigmentation. The hallmark of pigmented purpuric dermatoses is their orange-brown, speckled, cayenne pepper-like discoloration.
Subject(s)
Foot Dermatoses/etiology , Hand Dermatoses/etiology , Leg Dermatoses/etiology , Purpura/complications , Skin Diseases, Vascular/complications , Vasculitis/complications , Arm , Churg-Strauss Syndrome/complications , Churg-Strauss Syndrome/pathology , Embolism/complications , Granulomatosis with Polyangiitis/complications , Humans , IgA Vasculitis/complications , IgA Vasculitis/diagnosis , IgA Vasculitis/therapy , Pigmentation Disorders/complications , Pigmentation Disorders/diagnosis , Pigmentation Disorders/pathology , Polyarteritis Nodosa/complications , Polyarteritis Nodosa/pathology , Purpura/diagnosis , Purpura/pathology , Purpura Fulminans/complications , Vasculitis/diagnosis , Vasculitis/drug therapy , Vasculitis/pathologyABSTRACT
BACKGROUND: Melanoma is a common type of skin cancer with poor survival in advanced stages. Screening efforts aim to detect and tackle tumors at an early stage. However, regional population-based data at the time of initial diagnosis are sparse. OBJECTIVES: To analyse clinical and pathologic tumor characteristics in a Swiss population. MATERIALS AND METHODS: Melanoma samples diagnosed at a large Swiss academic department were evaluated for demographic, clinical and histopathologic data. RESULTS: We analysed a total of 254 melanoma samples. In situ tumors were more common in females than in males (70.6% vs. 29.4%; p = 0.0032). The acro-lentiginous subtype was more common in in situ compared to invasive tumors (14.7% vs. 5.5%; p = 0.0011). Invasive tumors showed a preference for male gender in patients beyond 60 years of age (p = 0.0080). The most frequent anatomic sites were the trunk in males and the legs in females. Regression was more common in males than in females (35.2% vs. 11.7%; p = 0.0001). Breslow's thickness correlated significantly with age but not with gender. Ulceration was common in tumors thicker than 2.01 mm (48.4%; p = 0.0001). Regression was frequently detected in melanomas thinner than 1.00 mm (29.3%; p = 0.0263). CONCLUSION: Screening efforts should target elderly patients. Skin examinations should include acral localisations and focus on the trunk in males and the lower extremities in females. Population-based analyses can help to fine-tune melanoma screening in defined regional populations.
Subject(s)
Melanoma/pathology , Skin Neoplasms/pathology , Adult , Age Factors , Aged , Aged, 80 and over , Early Detection of Cancer , Female , Humans , Leg , Male , Melanoma/complications , Middle Aged , Neoplasm Invasiveness , Neoplasm Staging , Sex Factors , Skin Neoplasms/complications , Skin Ulcer/etiology , Skin Ulcer/pathology , Switzerland , TorsoABSTRACT
BACKGROUND: Treatment with selective BRAF or MEK inhibitors is frequently associated with cutaneous toxicities, including squamous cell carcinoma (SCC), papillomas and rash. These cutaneous adverse effects are typically observed at a lower incidence during combined BRAF and MEK inhibitor therapy. PATIENTS AND METHODS: Two male patients with stage IV metastatic BRAF-mutated melanoma were treated with a combination of a selective BRAF inhibitor and a selective MEK inhibitor (dabrafenib and trametinib, or encorafenib (LGX818) and binimetinib (MEK162)) within two different clinical trials. Ten and 150 days after treatment start respectively, the patients developed painful nodules on the legs. In addition, one patient developed symmetrical articulation pain and intermittent fever episodes. RESULTS: Based on the clinical and histological presentation, erythema nodosum-like panniculitis was diagnosed in both cases. No other aetiology could be found. After receiving topical or oral steroid treatment and anti-inflammatory analgesics, the painful nodular lesions disappeared several weeks later. In one case, a rebound of the painful nodules was observed when the combination treatment (dabrafenib and trametinib) was resumed after a 1-week unscheduled treatment interruption. CONCLUSIONS: Panniculitis has previously been described in association with BRAF inhibitor treatment, but not MEK inhibitor treatment. Combination treatment is usually associated with a lower incidence of cutaneous adverse events (AEs), as compared to monotherapy. Panniculitis was observed in two patients during combined BRAF and MEK inhibitor treatment. These cases illustrate the need for further research in a larger patient population to identify a possible link between combined BRAF and MEK inhibitor treatment and the incidence of panniculitis.
Subject(s)
Antineoplastic Combined Chemotherapy Protocols/adverse effects , Melanoma/drug therapy , Panniculitis/chemically induced , Proto-Oncogene Proteins B-raf/genetics , Skin Neoplasms/drug therapy , Adult , Benzimidazoles/administration & dosage , Carbamates/administration & dosage , Humans , Imidazoles/administration & dosage , Male , Melanoma/genetics , Melanoma/secondary , Mitogen-Activated Protein Kinases/antagonists & inhibitors , Oximes/administration & dosage , Proto-Oncogene Proteins B-raf/antagonists & inhibitors , Pyridones/administration & dosage , Pyrimidinones/administration & dosage , Skin Neoplasms/genetics , Skin Neoplasms/pathology , Sulfonamides/administration & dosageABSTRACT
A 52-year-old Colombian woman, a patient with psoriasis, undergoing phototherapy with (ultraviolet B narrowband) UVBnb, presented with a symptomless solitary diffuse erythaematous plaque on her nose for 3â months. Initially, she was treated with pimecrolimus 1% cream for 8â weeks, which was then combined with metronidazole cream for 4â weeks, with the initial diagnosis of UV-triggered rosacea, without improvement. A punch biopsy was performed and the histology showed a pseudolymphomatous reaction. The diagnosis of nasal pseudolymphoma of borreliosis was confirmed with PCR. The lesion completely resolved following oral doxycycline therapy.
Subject(s)
Lyme Disease/complications , Nose Diseases/diagnosis , Pseudolymphoma/diagnosis , Rosacea/diagnosis , Anti-Bacterial Agents/therapeutic use , Borrelia burgdorferi , Diagnosis, Differential , Doxycycline/therapeutic use , Female , Humans , Lyme Disease/drug therapy , Middle Aged , Nose Diseases/microbiology , Pseudolymphoma/microbiologySubject(s)
Hydroxychloroquine/administration & dosage , Lymphoma, Non-Hodgkin/drug therapy , Lymphoma, T-Cell, Cutaneous/drug therapy , Lymphoma, T-Cell, Cutaneous/pathology , Skin Neoplasms/drug therapy , Skin Neoplasms/pathology , Antimalarials/administration & dosage , Biopsy, Needle , CD8 Antigens/immunology , Dose-Response Relationship, Drug , Drug Administration Schedule , Follow-Up Studies , Humans , Immunohistochemistry , Lymphoma, Non-Hodgkin/diagnostic imaging , Lymphoma, Non-Hodgkin/pathology , Lymphoma, T-Cell, Cutaneous/diagnostic imaging , Male , Middle Aged , Neoplasm Invasiveness/pathology , Neoplasm Staging , Positron-Emission Tomography/methods , Skin Neoplasms/diagnostic imaging , Switzerland , Treatment OutcomeABSTRACT
Clonal selection and transcriptional reprogramming (e.g., epithelial-mesenchymal transition or phenotype switching) are the predominant theories thought to underlie tumor progression. However, a "division of labor" leading to cooperation among tumor-cell subpopulations could be an additional catalyst of progression. Using a zebrafish-melanoma xenograft model, we found that in a heterogeneous setting, inherently invasive cells, which possess protease activity and deposit extracellular matrix (ECM), co-invade with subpopulations of poorly invasive cells, a phenomenon we term "cooperative invasion". Whereas the poorly invasive cells benefit from heterogeneity, the invasive cells switch from protease-independent to an MT1-MMP-dependent mode of invasion. We did not observe changes in expression of the melanoma phenotype determinant MITF during cooperative invasion, thus ruling out the necessity for phenotype switching for invasion. Altogether, our data suggest that cooperation can drive melanoma progression without the need for clonal selection or phenotype switching and can account for the preservation of heterogeneity seen throughout tumor progression.
Subject(s)
Cell Movement , Cellular Reprogramming , Melanoma/pathology , Animals , Cell Line, Tumor , Extracellular Matrix/metabolism , Humans , Matrix Metalloproteinase 14/genetics , Matrix Metalloproteinase 14/metabolism , Melanocytes/classification , Melanocytes/physiology , Melanoma/metabolism , Microphthalmia-Associated Transcription Factor/genetics , Microphthalmia-Associated Transcription Factor/metabolism , Neoplasm Invasiveness , Phenotype , ZebrafishSubject(s)
Hemangioma, Cavernous, Central Nervous System/genetics , Keratosis/genetics , Microtubule-Associated Proteins/genetics , Mutation , Proto-Oncogene Proteins/genetics , Skin Diseases, Vascular/genetics , Adult , Hemangioma, Cavernous, Central Nervous System/complications , Humans , KRIT1 Protein , Keratosis/complications , Male , Skin Diseases, Vascular/complicationsABSTRACT
BACKGROUND: Botryomycosis is a rare infectious disease which usually affects the skin. The low virulence of the bacteria tending to form grains and the immune status of the host are important factors in the development of the disease. METHODS: We report a case of cervicofacial botryomycosis and review the current literature. RESULTS: A 47-year-old male with a long history of moderate-to-severe atopic dermatitis presented with painful and suppurative nodules of the head and neck. A skin biopsy revealed granules consisting of Gram-positive bacterial colonies in a blossom-like assembly in the center and an eosinophilic rim in the periphery, which are pathognomonic features of botryomycosis. The lesions responded well to systemic antibiotics; however, they rapidly relapsed upon cessation of the treatment. CONCLUSIONS: We highlight the well-defined histologic features and recall an almost forgotten disease. We review common predisposing conditions and present evidence that atopic dermatitis might be an additional predisposing factor.
ABSTRACT
PURPOSE: Vemurafenib is a potent inhibitor of V600 mutant BRAF with significant impact on progression-free and overall survival in advanced melanoma. Cutaneous side effects are frequent. This single-center observational study investigates clinical and histological features of these class-specific cutaneous adverse reactions. PATIENTS AND METHODS: Patients were all treated with Vemurafenib 960 mg b.i.d. within local ethic committees approved clinical trials. All skin reactions were collected and documented prospectively. Cutaneous reactions were classified by reaction pattern as phototoxic and inflammatory, hair and nail changes, keratinocytic proliferations and melanocytic disorders. RESULTS: Vemurafenib was well tolerated, only in two patients the dose had to be reduced to 720 mg due to arthralgia. 26/28 patients (93%) experienced cutaneous side effects. Observed side effects included UVA dependent photosensitivity (nâ=â16), maculopapular exanthema (nâ=â14), pruritus (nâ=â8), folliculitis (nâ=â5), burning feet (nâ=â3), hair thinning (mild alopecia) (nâ=â8), curly hair (nâ=â2) and nail changes (nâ=â2). Keratosis pilaris and acanthopapilloma were common skin reactions (nâ=â12/nâ=â13), as well as plantar hyperkeratosis (nâ=â4), keratoacanthoma (nâ=â5) and invasive squamous cell carcinoma (nâ=â4). One patient developed a second primary melanoma after more than 4 months of therapy (BRAF and RAS wild type). CONCLUSION: Vemurafenib has a broad and peculiar cutaneous side effect profile involving epidermis and adnexa overlapping with the cutaneous manifestations of genetic diseases characterized by activating germ line mutations of RAS (RASopathy). They must be distinguished from allergic drug reaction. Regular skin examination and management by experienced dermatologists as well as continuous prophylactic photo protection including an UVA optimized sun screen is mandatory.
Subject(s)
Indoles/adverse effects , Skin Diseases/chemically induced , Skin Diseases/genetics , Sulfonamides/adverse effects , ras Proteins/genetics , Adult , Aged , Cell Proliferation/drug effects , Female , Hair/drug effects , Humans , Keratinocytes/drug effects , Keratinocytes/pathology , Male , Melanocytes/drug effects , Melanocytes/pathology , Middle Aged , Nails/drug effects , Skin Diseases/pathology , Time Factors , Vemurafenib , Young AdultABSTRACT
Deregulated Ras signaling initiates and maintains melanocyte neoplasia. The Rho-like GTPase Rac has been implicated in Ras-induced neoplastic transformation. Moreover, a recurrent UV-induced mutation activating RAC1 has recently been detected in human melanoma. Here, a role for Rac in melanoma initiation and progression was investigated in human melanomas and zebrafish models of melanocyte neoplasia. Immunohistochemical analysis revealed RAC expression and activity restricted to melanocytes at the junction of the epidermis and dermis in benign neoplasms. Malignant melanocytes displayed elevated RAC activity that extended into the suprabasal epidermis, deeper into the dermis, and was maintained in metastases. Previously, we have used zebrafish transgenic models to demonstrate that deregulated Ras/Raf/mitogen-activated protein kinase signaling can initiate melanocyte neoplasia. Expression of a constitutively active RAC1 mutant (V12RAC1) was not sufficient to initiate melanocyte neoplasia in this organism. Furthermore, we did not detect an additive effect when combined with V600EBRAF, nor could V12RAC1 substitute for suppressed Pi3k signaling to restore melanoma progression. However, coexpression of V12RAC1 and oncogenic RAS accelerated tumor nodule formation. Immunohistochemical analysis revealed that the Rac activator Tiam1 (T-cell lymphoma invasion and metastasis 1) is overexpressed in melanoma tumor nodules in both zebrafish and humans. Thus, our data suggest that Rac contributes to the progression of melanoma and that Tiam1 may activate Rac in nodular presentations.
Subject(s)
Melanocytes/pathology , Melanoma/pathology , Signal Transduction/physiology , Skin Neoplasms/pathology , Zebrafish Proteins/genetics , Zebrafish Proteins/metabolism , rac1 GTP-Binding Protein/genetics , rac1 GTP-Binding Protein/metabolism , Animals , Animals, Genetically Modified , Cell Line, Tumor , Disease Progression , Fibroblasts/cytology , Fibroblasts/physiology , Guanine Nucleotide Exchange Factors/genetics , Guanine Nucleotide Exchange Factors/metabolism , HEK293 Cells , Humans , Melanocytes/physiology , Melanoma/metabolism , Melanoma/physiopathology , Mice , Neoplasm Invasiveness/pathology , Neoplasm Invasiveness/physiopathology , Skin Neoplasms/metabolism , Skin Neoplasms/physiopathology , T-Lymphoma Invasion and Metastasis-inducing Protein 1 , ZebrafishABSTRACT
Survival of lymphocytes and melanocyte stem cells critically depends on B cell lymphoma 2 (Bcl-2). In T lymphocytes, a basal calcineurin activity maintains Bcl-2 expression in naïve cells, and the activation of the calcineurin pathway orchestrates the regulation of the intrinsic apoptosis pathway after antigen recognition. Therefore, calcineurin inhibitors might potentiate the pro-apoptotic effect of pharmacological Bcl-2 inhibitors on lymphatic cells. In vitro, a reduced Bcl-2 expression in lymphocytes exposed to calcineurin inhibitors increased their sensitivity to the small molecule Bcl-2 inhibitor ABT-737. This correlated with an augmented pro-apoptotic activity of ABT-737 on lymphocytes in combination with cyclosporine A in naïve mice in vivo. Interestingly, similar processes were observed in melanocytes. ABT-737 induced a fur depigmentation at the site of injection, and this effect was expanded to a generalized depigmentation in combination with cyclosporine A. Thus, inhibiting calcineurin increases the pro-apoptotic potency of ABT-737 in cells depending on Bcl-2 for survival. The increased efficacy of Bcl-2 inhibitors in combination with cyclosporine A might be relevant to exploit their anti-neoplastic and immuno-modulatory properties.
Subject(s)
Biphenyl Compounds/pharmacology , Cyclosporine/pharmacology , Nitrophenols/pharmacology , Proto-Oncogene Proteins c-bcl-2/antagonists & inhibitors , Sulfonamides/pharmacology , Animals , Apoptosis/drug effects , Calcineurin Inhibitors , Drug Synergism , Hair Color/drug effects , Lymphocytes/drug effects , Lymphocytes/pathology , Melanocytes/drug effects , Mice , Piperazines/pharmacologyABSTRACT
Three cases with CD8+ small- to medium-sized lymphoproliferations in the skin at extrafacial sites are described. Clinically, the patients presented with papulonodular or plaque-like lesions without preceding patches. Histopathologically, nonepidermotropic nodular or diffuse infiltrates were composed of small- to medium-sized pleomorphic lymphocytes, which expressed CD8 (more than 80% of the cells) and granzyme B (60%-70% of the cells), but were negative for CD4, CD30, and CD56. There was no association with Epstein-Barr virus. A clonal T-cell population was detected in 2 patients. Staging examinations did not reveal extracutaneous involvement. The 2 patients with solitary lesions underwent complete remission after radiation therapy, whereas 1 patient developed multifocal lesions and several recurrences. These CD8+ small- to medium-sized lymphoproliferations of the skin at extrafacial sites may belong to a spectrum of phenotypically and prognostically heterogeneous cutaneous small- to medium-sized lymphoid proliferations, which are characterized by an indolent course in most patients.
Subject(s)
Lymphoproliferative Disorders/classification , Lymphoproliferative Disorders/pathology , Skin Diseases/classification , Skin Diseases/pathology , Aged, 80 and over , CD8-Positive T-Lymphocytes/immunology , Female , Humans , Immunohistochemistry , Lymphoproliferative Disorders/immunology , Male , Middle Aged , Skin Diseases/immunologyABSTRACT
BACKGROUND: Solid organ transplant recipients are at an increased risk for infections because of long-term immunosuppression to prevent graft rejection. Fungal infections with dermatophytes are a common cause of cutaneous infections seen in organ transplant recipients and cutaneous dermatophyte infections may progress to Majocchi's granuloma. Itraconazole is an anti-fungal compound used for the treatment of infections of the skin, nails and mucous membranes. MAIN OBSERVATION: We report on a heart transplant recipient who developed widespread Trichophyton rubrum infection presenting as Majocchi's granuloma. Itraconazole treatment was complicated by drug interactions. Tricho-phyton rubrum infection progressed, while itraconazole treatment was varied in dose and delivery form. CONCLUSIONS: In patients with Trichophyton rubrum infections, refractory to itraconazole treatment, altered drug absorption or drug interactions has to be considered. Careful monitoring and adjustment of itraconazole is of vital importance.
ABSTRACT
BACKGROUND: Transepidermal melanocytic migration (TEM) is an important diagnostic criterion for malignancy, especially in association with cytologic atypia. However, TEM may also be observed in benign melanocytic tumors, such as Spitz nevus, acral nevi, or nevi in infancy. We discuss the value of TEM for the diagnosis of melanocytic tumors in a young patient previously diagnosed as having 11 cutaneous melanomas. OBSERVATION: A 17-year-old patient with a history of 11 cutaneous melanomas diagnosed in the past 3 years by different expert dermatopathologists presented in our department. The previous histological diagnoses of melanoma were mainly based on the presence of important TEM. A reevaluation of all histological specimens in light of the clinical context and the lack of genomic aberrations as detected by array-comparative genomic hybridization led to a revision of the previous diagnoses. The striking TEM observed represents, in our opinion, a constitutional element of the melanocytic nevi in this patient and not a marker of malignancy. CONCLUSION: Awareness of this finding is important to avoid overdiagnosis of melanoma in cases of melanocytic nevi.